APGE - Apogee Therapeutics, Inc.


68.5
-2.415   -3.526%

Share volume: 1,173,789
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%

$70.92
-2.42
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
33%
Profitability 35%
Dept financing 19%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-2.14%
1 Month
5.58%
3 Months
-9.27%
6 Months
84.49%
1 Year
125.55%
2 Year
64.11%
Key data
Stock price
$68.50
P/E Ratio 
0.00
DAY RANGE
$66.76 - $70.29
EPS 
-$4.12
52 WEEK RANGE
$26.20 - $84.56
52 WEEK CHANGE
$117.94
MARKET CAP 
2.368 B
YIELD 
N/A
SHARES OUTSTANDING 
81.807 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-11-2025
BETA 
1.84
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$774,910
AVERAGE 30 VOLUME 
$849,263
Company detail
CEO: Michael Henderson
Region: US
Website: apogeetherapeutics.com
Employees: 0
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Apogee Therapeutics, Inc. was incorporated under the laws of the State of Delaware on June 9, 2023. It had no business operations prior to this offering. We are a fully remote company and do not maintain physical corporate offices. Our employees work remotely from home. We maintain a mailing address at 221 Crescent St., Building 17, Suite 102b, Waltham, MA.

Recent news